Elemental Isomerism: A Boron-Nitrogen Surrogate for a Carbon-Carbon Double Bond Increases the Chemical Diversity of Estrogen Receptor Ligands  by Zhou, Hai-Bing et al.
Chemistry & Biology
ArticleElemental Isomerism: A Boron-Nitrogen Surrogate
for a Carbon-Carbon Double Bond Increases the
Chemical Diversity of Estrogen Receptor Ligands
Hai-Bing Zhou,1,6 Kendall W. Nettles,3,6 John B. Bruning,3 Younchang Kim,4 Andrzej Joachimiak,4
Sanjay Sharma,5 Kathryn E. Carlson,1 Fabio Stossi,2 Benita S. Katzenellenbogen,2 Geoffrey L. Greene,5
and John A. Katzenellenbogen1,*
1 Department of Chemistry
2 Departments of Molecular and Integrative Physiology and Cell and Developmental Biology
University of Illinois, Urbana, IL 61801, USA
3 Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA
4 Midwest Center for Structural Genomics and Structural Biology Center, Argonne National Laboratory, Argonne, IL 60439, USA
5 Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA
6 These authors contributed equally to this work.
*Correspondence: jkatzene@uiuc.edu
DOI 10.1016/j.chembiol.2007.04.009SUMMARY
To increase the chemical diversity of bioactive
molecules by incorporating unusual elements,
we have examined the replacement of a C=C
double bond with the isoelectronic, isostruc-
tural B-N bond in the context of nonsteroidal
estrogen receptor (ER) ligands. While the B-N
bond was hydrolytically labile in the unhindered
cyclofenil system, the more hindered anilino
dimesitylboranes, analogs of triarylethylene
estrogens, were easily prepared, hydrolytically
stable, and demonstrated substantial affinity
for ERs. X-ray analysis of one ERa-ligand com-
plex revealedstericclasheswith theparamethyl
groups distorting the receptor; removal of these
groups resulted in an increase in affinity, po-
tency, and transcriptional efficacy. These stud-
ies define the structural determinants of stability
and cellular bioactivity of a B-N for C=C substi-
tution in nonsteroidal estrogens and provide
a framework for further exploration of ‘‘elemen-
tal isomerism’’ for diversification of drug-like
molecules.
INTRODUCTION
The preparation of small molecules with cell-regulatory
activities—agonists, antagonists, drugs, etc.—is a major
component of ‘‘chemical genomics’’ and has as its ulti-
mate goal the development of ligands capable of selective
regulation of the activity of all important protein targets [1].
Efforts to prepare small-molecule regulators of increas-
ingly broad biological activity demand new approaches
and concepts to increase the structural and chemical di-
versity; these efforts have included high-throughput com-
binatorial synthesis and diversity-oriented synthesis [2].Chemistry & Biology 14, 6Less developed have been efforts to increase the elemen-
tal diversity of drug-like molecules. In this work, we have
examined the introduction of boron—specifically the iso-
electronic and isostructural replacement of a C=C bond
with a B-N bond—as a core structural element in bioactive
ligands and have used nonsteroidal ligands for the estro-
gen receptor (ER) as a context. In these examples of
‘‘elemental isomerism,’’ we have addressed the questions
of whether the B-N analogs can be readily prepared, are
stable, and retain structural characteristics consistent with
biological activity.
Although boron is not an element commonly found in
natural products or drugs, bioactive boron-containing
compounds are known (Figure 1). The natural product bor-
omycin and its relatives [3] are antibiotics and potential
antivirals [4]. Borinic esters and oxazaborolidines with
antibacterial activity are known [5, 6], and a benzoxaborole
is being studied for onychomycosis [7]. Certain a-amino-
boronic acids [8] and related agents have anticancer,
hypolipidemic, and antifungal activity; diazaborines are
antimalarials [9, 10], and others are protease [11] and pro-
teosome inhibitors [12]. L-p-borono-phenylalanine and
molecules with the compact B10H10C2 carborane unit are
of interest in boron-neutron capture therapy [13, 14]; the
carborane has also been used in some nonsteroidal estro-
gens [15, 16].
Because of its inherently electrophilic character, the bo-
ron atom in most of these structures is tethered to a small-
molecule unit through multiple single bonds to oxygen- or
nitrogen-donor atoms, with boron thus being—formally—
a boronate anion or a mixed boronic acid amide-ester. In
some boronic acids, the electrophilic nature of the boron
is also the key to its bioactivity [11, 12].
We were intrigued by another boron-containing entity,
the boron-nitrogen (B-N) bond. The B-N bond is isoelec-
tronic with the C=C double bond, and, curiously, at least
with boron-10, which accounts for 20% of boron at natural
abundance, the 10B-14N system has the same number of
protons and neutrons as the 12C-12C system. Structural59–669, June 2007 ª2007 Elsevier Ltd All rights reserved 659
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Elemental Isomerism, B-N as a Surrogate for C=CFigure 1. Boron-Containing Bioactive
Moleculesstudies have also shown that pp-pp bonding in B-N com-
pounds gives partial double-bond character to the B-N
bond that restricts rotation (Figure 2, left). This suggests
that the isoelectronic substitution of a B-N bond for a C=C
bond will also be isostructural [17–19]. Although it is not
clear how hydrolytically stable the B-N bond will be, the
electrophilicity of the boron center should be moderated to
a considerable degree by electron donation from the nitro-
gen, and steric factors could play a role. As far as we are
aware, a B-N bond has not been used as a surrogate for
a C=C bond for the construction of bioactive molecules.
Certain nonsteroidal ligands for the ERthathavea C=C dou-
ble bondat their core,exemplified bythe 1,1-diarylethylenes
and the triarylethylenes (Figure 2, right, top), provide
convenient vehicles for examination of this isostructural-
elemental replacement (Figure 2, bottom, right).
The ERs, members of the superfamily of nuclear recep-
tors, have emerged as attractive pharmaceutical targets
for therapeutic intervention in a wide variety of diseases,
including osteoporosis and breast cancer [20]. Estrogens
act through two ER subtypes, ERa and ERb, which have
different tissue distributions and sequence differences in660 Chemistry & Biology 14, 659–669, June 2007 ª2007 Elsevietheir ligand-binding domain [21]. Estrogens can have re-
markable tissue-selective effects, which has led to the
development of compounds, termed selective ER modu-
lators (SERMs) [22], that function as estrogen agonists in
some tissues (bone, brain, and the cardiovascular sys-
tem), but as antagonists in others (uterus and breast)
[23, 24]. The ERs can bind a variety of steroidal and non-
steroidal ligands, and the search for better SERMs has
driven efforts to increase the chemical diversity of these
ligands, especially the nonsteroidal ones.
In this report, we describe the facile synthesis of ele-
mental analogs of the di- and triarylethylene moieties of
nonsteroidal estrogens, wherein the central C=C bond
has been replaced by a B-N bond. We anticipated that
the aminoborane structural surrogates shown in Figure 2
would possess structures similar to those of the known
C=C ligands on which they were based, and we hoped
that they would be stable compounds with interesting bi-
ological activity. We have found that these compounds
can be readily prepared, that the hydrolytic lability of the
B-N bond can be moderated by steric shielding of the bo-
ron center, and that ligands with high ER affinity and goodFigure 2. B-N Bond for C=C Bond Replacement and Di- and Triarylethylene
Comparison of p-bond systems, resonance forms, proposed mechanism of B-N hydrolysis, and nonsteroidal estrogens and their B-N analogs.r Ltd All rights reserved
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of the binding affinity and efficacy of these ER ligands in
which the B-N bond was substituted for the C=C double
bond was aided by X-ray crystallographic analysis of the
complex of one B-N analog with ERa.
RESULTS
Chemical Synthesis
Piperidino Diarylboranes, B-N Analogs
of 1,1-Diarylethylene Estrogens
To prepare compounds 4 (Figure 3), dimethyldiaryltins 1
were treated with BCl3, furnishing diarylchloroboranes 2,
which reacted with piperidine (3) to give compounds 4.
These piperidine diarylboranes, however, were very sensi-
tive to moisture and quickly decomposed in methanol.
To block hydroxyl attack on the unhindered boron center
(Figure 2), we replaced the B-aryl groups with the hindered
2,4,6-trimethylphenyl (mesityl, Mes) groups. Dimesitylbor-
ane derivatives are known to be quite hydrolytically stable
[17, 18]. We also replaced the piperidine with p-hydroxya-
nilines, to make analogs of triarylethylene estrogens.
Anilino Dimesitylboranes, B-N Analogs
of Triarylethylene Estrogens
To synthesize anilino dimesiylboranes 8 and 9 (Figure 4A),
fluoro dimesitylborane (6), prepared by a literature method
from boron trifluoride etherate [18], was treated with the
lithium anions of the various anilines 7 [17]. Standard prod-
uct isolation gave the anilino boranes 8, which could be
purified by chromatography over neutral alumina. Deme-
thylation of 8c–8g with BF3$SMe2 proceeded at room
temperature without product decomposition.
Gratifyingly, the anilino dimesitylboranes (9c–9g) were
stable to air, water, dilute acid, and base (as well as to the
more vigorous phenol-deprotection conditions). Also of
note is the ease with which these highly hindered B-N
compounds can be prepared, especially compared to their
direct C=C analogs (see below).
Based on a crystal structure of compound 9e bound to
ERa, described below (Figure 5), we modified the aryl
groups attached to the boron atom: the two ortho methyl
groups were retained to stabilize the boron center against
hydrolysis, but the para methyl groups were either
substituted with methoxyl groups or were deleted to leave
Figure 3. Synthesis of Piperidino DiarylboranesChemistry & Biology 14, 6the rings unsubstituted at this site. The p-methoxyl ana-
logs were to be precursors of the corresponding triols
(14) in which one of the B-phenols might substitute for
the A-ring phenol of an estrogen (Figure 4B).
Bis(2,6-dimethy-4-methoxyphenyl)fluoroborane,10 [25],
was treated with anilines 7c and 7e to give the anilino bo-
ranes11aand11b.Wewere,however,unable toprepare the
corresponding anilino borane analogs 14 that had three free
phenols, because these derivatives decomposed during
demethylation. Notably, these B-N compounds were un-
stable to the same phenol-demethylation conditions used
to convert methyl ethers 8c–8g to phenols 9c–9g; they
were also unstable under milder deprotection conditions
(Me3SiI, etc.). Thus, introduction of a hydroxy group in the-
para position of the phenyl borane system must engender
some instability. Reaction of 10 with 4-methylamino-phe-
nol 12a afforded the bismethoxy-monophenol analog, 13.
The less bulky anilino boranes 16a–16c were also syn-
thesized in reasonable yields, respectively, by reaction of
7b, 12a, and 12c with bis(2,6-dimethyl)fluoroborane, 15
(Figure 4C) [26]. Remarkably and conveniently, the B-N
bonds in 13 and 16a–16c can be formed in the presence
of a free phenol.
Attempted Synthesis of the Carbon-Carbon
and Carbon-Nitrogen Analogs of the Anilino
Bis(2,6-dimethylphenyl)boranes
Because of the interesting binding and bioactivity of the
anilino diarylboranes (see below), we attempted to prepare
the corresponding C=C triarylethylene analog (compound
17; Figure S1; see the Supplemental Data available with
this article online) to evaluate more directly the effect of
the isoelectronic B-N for C=C substitution on these biolog-
ical parameters. The desired target compound (17) is,
however, a very highly hindered, tetrasubstituted alkene,
and thus far, we have been unable to prepare this molecule
by using either Grignard addition, McMurray coupling, or
thiadiazoline decomposition approaches, methods we
have used to prepare highly hindered, tetrasubstituted
diarylethylene nonsteroidal estrogens [27].
We also attempted to prepare a benzhydryl amine ana-
log of the B-N compounds (19; Figure S1) by reacting N-
methyl-p-methoxyaniline, 7c, with the benzhydryl chloride,
18. Upon demethylation, this would give a C-N analog of
compound 16b. This reaction was very sluggish, and after
3 days of reflux in acetonitrile, we obtained a new com-
pound in low yield that was not the desired amine but
rather the related imine (compound 20), which could be
characterized unmistakably by 1H and 13C NMR and mass
spectrometry. Compound 20 represents a product of for-
mal oxidative N-demethylation, and the mechanism for its
formation is not obvious. The corresponding free phenol,
21, was obtained by the demethylation of compound 20.
X-Ray Crystal Structure of Dimesitylborane 9e
We were able to obtain a crystal structure of anilino borane
9e as a complex with the ERa-ligand-binding domain
(LBD) (Figure 5). With a resolution cutoff of 2.7 A˚, the struc-
ture was refined to an R factor/Rfree of 23.1%/29.7%
(Table 1), indicating an acceptable fit of the structural59–669, June 2007 ª2007 Elsevier Ltd All rights reserved 661
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Elemental Isomerism, B-N as a Surrogate for C=CFigure 4. Synthesis of Anilino Diarylboranesmodel into the electron density data. This structure, ob-
tained in the presence of a coactivator peptide from the
NR2 box of the SRC-2/GRIP-1 coactivator [28], which
assists in crystallization of some ER-ligand complexes,
helped us understand how these novel B-N analogs of tri-
arylethylene estrogens bind to the ER. The ERa-LBD used
for this structure work contained an engineered point mu-
tation (Y537S) on the surface of the receptor [29]. Because
it is more stable, this ERa-LBD can be expressed at very
high levels in an active, unliganded form, which is a great
advantage for crystallographic studies, and elsewhere we662 Chemistry & Biology 14, 659–669, June 2007 ª2007 Elsevihave shown that this ER mutant retains ligand-binding
behavior equivalent to that of wild-type ER [30]. Further
description of the utility of the Y537S ER mutant in crystal-
lographic studies and the comparability of its structures
with ligands to wild-type ER will be described elsewhere
(K.W.N et al., unpublished data).
In the anilino borane 9e-ERa-LBD complex, the receptor
adopts a conformation that superficially resembles those
of other ER agonist complexes (Figure 5A), but with distor-
tions of the protein that are suggestive of a suboptimal fit of
the ligand. The anilino borane molecule is roughly Xer Ltd All rights reserved
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Elemental Isomerism, B-N as a Surrogate for C=CFigure 5. X-Ray Structure of Compound 9e Bound to ERa
(A) The ligand-binding domain of ERa is shown as a ribbon diagram; the bound compound 9e is shown as a stick figure.
(B) Comparison of the X-ray crystallographic structure of anilino dimesitylborane (9e) complexed with ERa-ligand-binding domain with the diethyl-
stilbestrol (DES) ERa structure [28]. The compound 9e-ER structure is atom color coded by CPK; the ligand and selected residues in the pocket
are shown. For the ligand, the boron is colored purple, and the fluorines are colored green. The DES molecule is colored green, and the corresponding
ER amino acids are colored yellow. The structures were superimposed over all backbone residues by using SwissPDBViewer.shaped (atom-colored structure, Figure 5B), and each axis
of the ‘‘X’’ distorts the ligand-binding pocket because of
certain unfavorable steric interactions. As a result, the
Table 1. Summary of Crystallographic Statistics
Data Collection
Beamline APS-19BM
Space group P 1 21 1
Unit cell (A˚) 55.55 3 79.80 3 58.33
Resolution (A˚) 12–2.70
Unique reflections 12,322
Average redundancy 3.6/3.1
Completeness (%) 93.2/82.3
Rmerge 0.109/0.4
I/s 11.4/2.27
Refinement
Resolution (A˚) 19–2.7
Rfree/R factor 23.1/29.7
Average B factor 22
RMS deviations
Bonds 0.010
Angles 1.381
Ramachandran analysis
Disallowed 0Chemistry & Biology 14,ligand-binding pocket is enlarged (717 A˚3 with compound
9e), which is ca. 200 A˚3 greater than what is typical for ER-
agonist ligand complexes: 501 A˚3 for genistein-ERa-LBD
(also with Y537S ERa; unpublished data) and 517 A˚3 for
DES-ERa-LBD (wild-type sequence) [28].
In all of the published ER structures, a phenol group
forms a strong hydrogen bond network with E353, R394
(in ERa), and a highly conserved water molecule. In our
structure, however, the phenolic oxygen of compound 9e
is a full angstrom further away from E353 (3.5 A˚), com-
pared to the typical distance of 2.5 A˚ seen in other struc-
tures (Figure 5B, compare compound 9e in gray with di-
ethylstilbestrol in green). Methyl group #1 prevents the
ligand from entering more deeply into the pocket because
of a close contact with A350. Methyl #1 and the trifluoro-
methyl group also distort the pocket, increasing the dis-
tance between L540 and I424, F425, and L428. A second
distortion of the pocket occurs from the steric influence of
Methyl #2, which repositions the backbone of helix 11 and
the side chains of helix 11 residues H524 and L525. Elec-
tron density maps of the ligand and receptor-binding site
residues illustrating these steric interactions are shown
in the Supplemental Data (Figure S2). Thus, although the
complex of anilino borane 9ewith ERa-LBD has an overall
agonist-like topology, the pocket is considerably distorted
from that typically seen with good ER agonists, because of
the steric clashes between binding pocket residues and
the two para-disposed methyl groups (Figure 5B, #1 and
#2). These two steric interactions would be expected to
reduce ligand-binding affinity, and the distortions that
they induce in the ligand-binding pocket, particularly the659–669, June 2007 ª2007 Elsevier Ltd All rights reserved 663
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Entry Compound ERa ERb a/b Ratio
1 8a <0.003 0.008 —
2 8b 0.013 ± 0.001 0.183 ± 0.006 0.07
3 9c 1.3 ± 0.2 3.1 ± 0.8 0.4
4 9d 1.25 ± 0.01 1.12 ± 0.01 1.1
5 9e 2.24 ± 0.08 1.34 ± 0.38 1.7
6 9f 0.16 ± 0.04 0.120 ± 003 1.3
7 9g 0.17 ± 0.03 0.29 ± 0.09 0.6
8 11a 0.01 0.009 1
9 13 2.0 ± 0.51 1.3 ± 0.5 1.5
10 16a 1.67 ± 0.05 0.996 ± 0.05 1.7
11 16b 23 ± 0.01 16 ± 3.7 1.4
12 16c 10.15 ± 0.02 5.8 ± 1.5 1.7
13 21 0.21 ± 0.05 0.45 ± 0.26 0.47
Relative binding affinity (RBA) is IC50
estradiol/IC50
compound 3 100. The KD for estradiol is 0.2 nM (ERa) and 0.5 nM (ERb) [30, 32]. Ki
values for the new compounds can be readily calculated by using the formula: Ki = (KD[estradiol]/RBA) 3 100.movement of helix 11 [31], also suggest that the agonist
activity of this compound is not likely to be optimal.
The two ‘‘offending’’ para-disposed methyl groups, un-
like the ortho-disposed methyls, are not essential for pro-
tecting the boron center from hydrolysis and thus could be
removed without affecting the hydrolytic stability of the
anilino borane functionality. We anticipated that their re-
moval would relieve the unfavorable ligand-protein steric
interactions and thus result in a tighter, more compact
complex, which should have the more typical 500 A˚3 inter-
nal volume found with ER-agonist structures. We also
thought that this change in ligand structure might allow
the phenolic hydroxyl to interact in a more normal manner
with E353, giving a stronger electrostatic interaction that
should increase affinity. In addition, because we previ-
ously identified helix 11 as an allosteric modulator of helix
12 [31], we imagined that the more appropriately sized,
undistorted ligand-binding pocket expected to form
around the smaller anilino borane would have helix 11
properly positioned, and thus might give a complex that
would produce a higher level of efficacy in transcription
assays. Therefore, we prepared the additional series of an-
iline bis(2,6-dimethylphenyl)borane derivatives, as we have
described (16a–16c; Figure 4C), analogs of the dimesityl-664 Chemistry & Biology 14, 659–669, June 2007 ª2007 Elsevieboranes in which the p-methyl groups had been removed.
The consequence of this structure-guided design modifi-
cation on binding affinity and efficacy is detailed below.
It is of note that the orientation of the anilino borane 9e in
the ERa ligand-binding pocket is also unusual. Whereas
other triarylethylene ER ligands, such as hydroxytamoxi-
fen, place one of the geminally substituted phenyl groups
in the A-ring-binding subpocket [28], the anilino borane
uses the N-aryl group for this purpose. Undoubtedly, this
results from the fact that, in the anilino boranes, we can
prepare this as the only ring with a phenolic hydroxyl
group; we have been unable to prepare anilino diarylbor-
anes with hydroxyl groups on the B-aryl rings.
Binding Affinity
The binding affinities of the anilino diarylborane ligands for
both ERa and ERb, determined by a competitive radiomet-
ric binding assay [30, 32], are expressed as relative binding
affinity (RBA) values, in which estradiol has an affinity of
100% (Table 2). Affinities depend on the nature of the sub-
stituents on both the nitrogen atom and B-diaryl groups. As
is expected from the binding of many estrogens [33, 34],
good binding requires an N-monophenol (11a versus 13,
entries 8 and 9), with a strong dependence on the naturer Ltd All rights reserved
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Elemental Isomerism, B-N as a Surrogate for C=CFigure 6. Transcription Activation through ERa and ERb of Compounds 9c, 9e, 16b, and 16c
Human endometrial cancer cells (HEC-1) were transfected with expression vectors for ERa or ERb and the estrogen responsive gene 2xERE-pS2-Luc
and were incubated with the indicated ligand for 24 hr. Agonist assays are shown as solid lines, and antagonist assays (done in the presence of 1 nM
estradiol, E2) are shown as dashed lines. Values are the mean ± SD of two or more experiments, expressed as a percent of the activity of ERa and ERb
with 109 M E2, which is set at 100%.of the N-substituent. Regarding the nitrogen substituent,
the highest affinity is observed in ligands with smallN-alkyl
groups. For example, ligand 9c, with an N-methyl group,
gave RBA values of 1.3% and 3.1% for ERa and ERb, re-
spectively (Table 2, entry3), but binding affinityand subtype
selectivity then decreases with an increase in alkyl chain
length (namely, compounds 9d, 9f, and 9g), the exception
being the N-trifluoroethyl compound 9e, which showed
somewhat improved affinity and selectivity for ERa.
As anticipated from the X-ray structure, the para substit-
uent on the B-aryl group has a big effect on binding affinity:
analogs with para-disposed Me and MeO groups give sim-
ilar, relatively modest affinities (9c and 13), whereas dele-
tion of the para groups resulted in a very marked increase
in binding affinity (16bversus9cand16c versus9e), which,
in the first case, was 20- and 14-fold on ERa and ERb, re-
spectively. Thus, elimination of the two groups responsible
for steric clashes noted in the crystal structure resulted in
significant increases in ER-binding affinities. In the one
comparison we can make between a B-N compound and
a C=N analog, it is apparent that the B-N compound (16a)
binds better than the C=N analog (21), although the com-
parison is not exact, because compound 16a has an N-H
group, whereas compound21has only a nitrogen lone pair.
Transcriptional Activity
Some of the higher-affinity compounds were assayed for
transcriptional activity through ERa and ERb by cotrans-Chemistry & Biology 14,fection assays in human endometrial cancer cells (HEC-
1) [35]. Neither of the dimesitylborane compounds (9c
and 9e; Figures 6A and 6B) showed substantial agonist
activity, consistent with the proposed steric clash by the
two para methyl groups that distorts the ligand-binding
pocket, partially displacing helix 11 [31], and they ap-
peared to be ERb-selective antagonists, which, in them-
selves, comprise an interesting pharmacological class.
Also of interest were the activities of the less bulky ani-
lino borane derivatives, (16b and 16c) with the offending
p-methyl groups removed, which were predicted to form
a more compact structure with less distortion of helix 11.
Both of these compounds showed good ERa agonist ac-
tivity, but they were still nearly complete antagonists on
ERb (Figures 6C and 6D). Their potencies were also higher
than those of the more bulky dimesitylboranes (9c and 9e),
consistent with their higher binding affinity.
DISCUSSION
In this study, we have expanded the chemical diversity of
drug-like molecules by making an elemental substitution
of a B-N bond for a C=C double bond, a molecular re-
placement that is isoelectronic and potentially isostruc-
tural, but that heretofore has not been widely examined.
As a test system for this elemental substitution, we se-
lected nonsteroidal ligands for the ER because these mol-
ecules are structurally simple, have a C=C double bond at659–669, June 2007 ª2007 Elsevier Ltd All rights reserved 665
Chemistry & Biology
Elemental Isomerism, B-N as a Surrogate for C=Ctheir core, and can be evaluated easily for their receptor-
binding affinity and cellular bioactivity.
We found that the synthesis of B-N for C=C substitution
analogs of members of the di- and triarylethylene nonste-
roidal estrogens could easily be accomplished, and that
the hydrolytic stability of the products was critically con-
trolled by steric hindrance of the boron atom of the B-N
bond. Although the electrophilic nature of the boron center
in the B-N bond is reduced by electron donation through
resonance from the nitrogen lone pair, it is still sufficiently
reactive to undergo hydrolysis when unhindered. Intro-
duction of flanking ortho methyl groups on both B-phenyl
substituents, however, provided sufficient steric screen-
ing to make these substituted analogs very stable in aque-
ous and other harsh environments, including the acidic
conditions used to deprotect aryl methyl ethers. Other as-
pects of their synthesis and stability were interesting. We
could prepare diaryl-B-N-alkyl/aryl systems in which the
aniline unit had a free p-hydroxy group simply by reacting
a fluoro diarylborane with an unprotected N-alkyl-p-hy-
droxyaniline, yet we were unable to prepare analogs hav-
ing a p-hydroxyl group on the B-phenyl groups because
these latter B-N compounds were unstable. Also, while
we could readily prepare the very hindered anilino diary-
lboranes with four ortho methyl groups flanking the boron
center, we were unable to prepare the corresponding C=C
(17) or C-N analogs (19). Attempts to prepare the latter
produced the diaryl-C=N-aryl compound through an
unusual net oxidation with loss of the N-alkyl group.
We were gratified that despite the extra alkyl substitu-
tion needed to stabilize the boron center from hydrolysis,
some of the anilino dimesitylboranes demonstrated signif-
icant, though not high binding affinity for the ERs. Fortu-
itously, we were able to obtain a crystal structure of one
of these compounds (9e) complexed with ERa that was
quite revealing. Because the only phenol we could intro-
duce into these systems was on the N-phenyl group,
this molecule was of necessity oriented in the ligand-bind-
ing pocket in a manner essentially the reverse that of other
triarylethylenes. Nevertheless, because of the open space
in the core of the ligand-binding pocket in the ERs, the four
ortho methyl groups did not suffer steric clashes with the
receptor [28, 36]. On the other hand, the two para methyl
groups in the mesityl substituents each appeared to
engage in steric clashes that distorted ligand binding
and receptor conformation.
We were able to eliminate these hypothesized disrup-
tive interactions by removing the para methyl groups from
the two B-aryl groups, and as predicted, the binding affin-
ity of all of these desmethyl analogs was greatly improved,
especially with ERa because the ligand-binding pocket of
ERa is larger than that of ERb [37]. Notably, as well, the po-
tency and level of agonism of the highest binding analogs
(16b,c) in cellular assays of ERa-regulated transcription
was also greatly improved, giving a compound with ERa
agonist and ERb antagonist activity, related to that of
R,R-tetrahydrochrysene, a compound described by us
earlier [38]. Thus, we were able to achieve a structure-
guided optimization of the biological activity of these B-N666 Chemistry & Biology 14, 659–669, June 2007 ª2007 Elseviecore ER ligands. Despite extensive efforts, however, we
have been unable to make a final verification of the struc-
tural basis of ligand improvement by obtaining a crystal
structure of ERa complexed with the desmethyl B-N
analog (16c).
SIGNIFICANCE
The regulation of all cellular activities by using small
molecules, the implicit goal of chemical genomics,
presents a challenge to chemists to create small-mol-
ecule libraries of increasing structural and functional
diversity. In this work, we have examined a different
approach—that of preparing elemental analogs of
known bioactive molecules by the isoelectronic and
isostructural replacement of a C=C bond with a B-N
bond. We have demonstrated the scope and limitation
of this approach in the context of nonsteroidal ligands
for the ER to determinewhether the B-N analogs could
be readily prepared, would be stable, and would retain
biological activity. These questions were all answered
in the affirmative, but with limitations of structure
required to sterically protect the electrophilic boron
center. Nevertheless, wewere able to prepare analogs
of triarylethylene nonsteroidal estrogens that retained
nanomolar binding affinity for both ERa and ERb. Our
optimization of affinity and bioactivity was assisted by
a crystal structure we obtained of an anilino dimesityl-
borane-ERa complex that revealed what appeared to
be unfavorable ligand-receptor steric clashes. With
this structural insight, we were able to redesign our
ligands, removing the groups responsible for these
unfavorable interactions, with the result that affinity,
potency, and bioactivity were greatly enhanced. The
favorable results we have obtained in challenging
biomedically important receptor targets with B-N for
C=C substitution elemental analogs of ligands should
provide encouragement for further evaluation of this
isoelectronic and isostructural bond replacement in
other biological contexts. The compounds are easy
to synthesize, in some cases much easier than their
C=C double bond analogs, and, with appropriate con-
siderations formoderatinghydrolytic stability, theyare
stable and bioactive. The introduction of this replace-
ment of the C=C bond with the B-N elemental analogs
should facilitate progress toward reaching the holy
grail of chemical genomics.
EXPERIMENTAL PROCEDURES
Materials and Methods
All reagents and solvents were obtained from Aldrich. Tetrahydrofuran,
diethyl ether, toluene, and dichloromethane were obtained prior to use
from a solvent-dispensing system [39]. Glassware was oven dried, as-
sembled while hot, and cooled under an inert atmosphere. Unless
otherwise noted, all reactions were conducted in an inert atmosphere.
Reaction progress was monitored with analytical thin-layer chroma-
tography (TLC) on 0.25 mm Merck F-254 silica gel glass plates. Visu-
alization was achieved by either UV light (254 nm) or a potassium per-
manganate indicator. Flash chromatography was performed withr Ltd All rights reserved
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6; bis(2,6-dimethylphenyl)fluoroborane, 15; bis(2,6-dimethy-4-
methoxyphenyl)fluoroborane, 10; and anilines 7d–7gwere synthesized
according to the literature (see Supplemental Data for the details).
1H NMR, 13C, 19F, and 11B NMR spectra were obtained on a 500,
400, or 300 MHz instrument. The chemical shifts are reported in ppm
and are referenced to either tetramethylsilane or the solvent. Mass
spectra were recorded under electron impact conditions at 70 eV.
Melting points were obtained on a Thomas-Hoover MelTemp appara-
tus and are uncorrected.
Synthesis of Anilino Diarylboranes
A solution of aniline 7 or 12 (0.1 mmol) in 5 ml ether was treated with
1.05 equivalents of a hexane solution of n-butyllithium (2.1 eq. for p-
hydroxylaniline 7b and 12a and 12c) under nitrogen atmosphere at
room temperature. A solution of diarylborane 6, 10, or 15 (1 eq.) in dry
ether was added to this solution, and the mixture was stirred for 30 min
[17]. The solution was then quenched by water, extracted three times
with 10 ml ethyl acetate, dried with potassium carbonate, and evapo-
rated to yield the crude product. The crude anilino borane products
were purified by passage through a column of neutral alumina with
hexanes-ethyl acetate as eluant. Demethylation of 8c–8g (0.1 mmol)
was conducted by using 30 equivalents of BF3$SMe2 in 5 ml dichloro-
methane at room temperature overnight. The reaction mixture was
quenched by 2 ml methanol and 5 ml water, extracted three times
with 10 ml ethyl acetate, and dried over K2CO3, and the pure product
was obtained by flash chromatography over neutral alumina or by
preparative alumina thin-layer chromatography.
(N-Methyl-p-methoxylanilino)dimesitylborane, 8c
Compound 8c was purified by flash chromatography over neutral alu-
mina (30% ethyl acetate/hexanes) to give a light-yellow needle (83%
yield) (mp 105C–107C); 1H NMR (400 MHz, CDCl3) d 6.97 (d, J =
9.0 Hz, 2H), 6.81 (s, 2H), 6.64 (d, J = 9.0 Hz, 2H), 6.56 (s, 2H), 3.73 (s,
3H), 3.21(s, 3H), 2.28 (s, 3H), 2.27 (s, 6H), 2.14 (s, 3H), 2.08 (s, 6H); 13C
NMR (100 MHz, CDCl3) d 156.39, 142.64, 140.71, 140.44, 137.22,
136.78, 128.13, 127.82, 125.74, 113.30, 55.50, 40.58, 22.81, 22.61,
22.30, 21.33; 11B NMR (96 MHz, CDCl3) d 43.69; MS (EI) m/z 385 (M
+,
10). HRMS (EI) calcd for C26H32BNO 385.257695, found 385.257084.
(N-Ethyl-p-methoxylanilino)dimesitylborane, 8d
Compound 8d was purified by flash chromatography over neutral alu-
mina (30% ethyl acetate/hexanes) to give a light-yellow solid (71%
yield) (mp 129C–130C); 1H NMR (500 MHz, CDCl3) d 6.96 (d, J =
9.0 Hz, 2H), 6.80 (s, 2H), 6.63 (d, J = 9.0 Hz, 2H), 6.54 (s, 2H), 3.72
(s, 3H), 3.64 (q, J = 7.2 Hz, 2H), 2.31 (s, 6H), 2.28 (s, 3H), 2.14 (s,
3H), 2.10 (s, 6H), 1.16 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3)
d 156.34, 141.62, 140.39, 137.04, 136.68, 128.15, 127.88, 126.16,
113.22, 55.45, 47.46, 22.93, 22.68, 21.27, 21.15, 16.44; 11B NMR (96
MHz, CDCl3) d 45.44; MS (EI) m/z 399 (M
+, 100). HRMS (EI) calcd for
C27H34BNO 399.27334, found 399.27469.
(N-2,2,2-Trifluoro-ethyl-p-methoxylanilino)dimesitylborane, 8e
Compound 8e was purified by flash chromatography over neutral alu-
mina (30% ethyl acetate/hexanes) to give a light-yellow solid (80%
yield) (mp 38C–40C); 1H NMR (500 MHz, CDCl3) d 7.15 (d, J = 9.0
Hz, 2H), 6.82 (s, 2H), 6.66 (d, J = 9.0 Hz, 2H), 6.58 (s, 2H), 4.11 (q,
J = 9.0 Hz, 2H), 3.71 (s, 3H), 2.29 (s, 6H), 2.28 (s, 3H), 2.17 (s, 6H),
2.15 (s, 3H); 13C NMR (125 MHz, CDCl3) d 157.20, 142.01, 140.42,
140.32, 137.94, 137.43, 128.62, 128.19, 126.80, 125.44 (q, J = 280.8
Hz), 113.62, 55.44, 54.99 (q, J = 128.5 Hz), 22.77, 22.66, 21.99,
21.17; 19F NMR (470 MHz, CDCl3) d 67.91; 11B NMR (96 MHz,
CDCl3) d 53.83; HRMS (ESI) calcd for C27H31BF3NO 453.24508, found
453.2429.
(N-Methyl-p-hydroxylanilino)dimesitylborane, 9c
Compound 9c was purified by preparative alumina thin-layer chroma-
tography (30% EtOAc/hexanes) to give a light-yellow solid (81% yield)
(mp 58C–60C); 1H NMR (500 MHz, CDCl3) d 6.90 (d, J = 9.0 Hz, 2H),
6.79 (s, 2H), 6.55 (d, J = 9.0 Hz, 2H), 6.53 (s, 2H), 4.58 (s, br, 1H), 3.18 (s,
3H), 2.26 (s, 3H), 2.25 (s, 6H), 2.13 (s, 3H), 2.05 (s, 6H); 13C NMR (125
MHz, CDCl3) d 152.29, 142.82, 140.70, 140.41, 137.24, 136.82, 128.12,Chemistry & Biology 14, 6127.80, 127.94, 114.84, 113.48, 40.51, 22.74, 22.23, 21.26, 21.18; 11B
NMR (96 MHz, CDCl3) d 42.64; HRMS (ESI) calcd for C25H30BNO
371.24204, found 371.2430.
(N-Ethyl-p-hydroxylanilino)dimesitylborane, 9d
Compound 9d was purified by preparative alumina thin-layer chroma-
tography (30% EtOAc/hexanes) to give a light-yellow solid (75% yield)
(mp 56C–58C); 1H NMR (500 MHz, CDCl3) d 6.90 (d, J = 8.5 Hz, 2H),
6.78 (s, 2H), 6.54 (d, J = 8.5 Hz, 2H), 6.52 (s, 2H), 4.54 (s, br, 1H), 3.61 (q,
J = 7.2 Hz, 2H), 2.29 (s, 6H), 2.26 (s, 3H), 2.12 (s, 3H), 2.08 (s, 6H); 13C
NMR (125 MHz, CDCl3) d 152.20, 141.75, 140.36, 137.04, 136.71,
128.13, 127.85, 126.35, 114.78, 113.48, 47.39, 22.90, 22.66, 21.25,
21.15, 16.36; 11B NMR (96 MHz, CDCl3) d 44.37; MS (EI) m/z 385 (M
+,
100). HRMS (EI) calcd for C26H32BNO 385.25769, found 385.257851.
(N-2,2,2-Trifluoro-ethyl-p-hydroxylanilino)dimesitylborane, 9e
Compound 9e was purified by preparative alumina thin-layer chroma-
tography (30% EtOAc/hexanes) to give a light-yellow solid (73% yield)
(mp 75C–77C); 1H NMR (500 MHz, CDCl3) d 7.06 (d, J = 8.5 Hz, 2H),
6.79 (s, 2H), 6.56 (d, J = 9.0 Hz, 2H), 6.54 (s, 2H), 4.67 (s, br, 1H), 4.06 (q,
J = 9.0 Hz, 2H), 2.26 (s, 3H), 2.25 (s, 6H), 2.13 (s, 9H); 13C NMR (125
MHz, CDCl3) d 153.18, 142.14, 140.37, 140.29, 137.94, 137.43, 128.58,
128.14, 127.03, 126.49 (q, J = 282.2 Hz), 115.17, 54.91 (q, J = 128.5
Hz), 22.71, 22.66, 21.98, 21.15; 19F NMR (470 MHz, CDCl3)
d 67.91; 11B NMR (96 MHz, CDCl3) d 52.50; MS (EI) m/z 439 (M+,
39). HRMS (EI) calcd for C26H29BF3NO 439.22943, found 439.22868.
(N-Methyl-p-hydroxylanilino)bis(2,6-dimethyl-4-
methoxylphenyl)borane, 13
Compound 13 was purified by flash chromatography over neutral alu-
mina (20% ethyl acetate/hexanes) to give a light-yellow solid (81%
yield) (mp 173C–175C); 1H NMR (400 MHz, CDCl3) d 6.95 (d, J =
8.8 Hz, 2H), 6.63 (d, J = 8.8 Hz, 2H), 6.54 (s, 2H), 6.30 (s, 2H), 3.78
(s, 3H), 3.72 (s, 3H), 3.68 (s, 3H), 3.19 (s, 3H), 2.27 (s, 6H), 2.07 (s,
6H); 13C NMR (100 MHz, CDCl3) d 159.83, 141.82, 127.78, 125.93,
122.67, 114.85, 113.48, 112.71, 112.37, 111.86, 55.30, 40.56, 22.62,
21.65; 11B NMR (96 MHz, CDCl3) d 44.36; MS (EI) m/z 403 (M
+, 10).
HRMS (EI) calcd for C25H30BNO3 403.23187, found 403.23277.
(N-Methyl-p-hydroxylanilino)bis(2,6-dimethylphenyl)borane,
16b
Compound 16b was purified by preparative alumina thin-layer chro-
matography (30% EtOAc/hexanes) to give a light-yellow solid (53%
yield) (mp 65C–67C); 1H NMR (400 MHz, CDCl3) d 7.11 (t, J = 7.2
Hz, 1H), 6.06 (d, J = 7.2 Hz, 2H), 6.92 (t, J = 7.2 Hz, 1H), 6.91 (d, J =
8.8 Hz, 2H), 6.72 (d, J = 7.6 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 4.52 (s,
1H), 3.20 (s, 3H), 2.30 (s, 6H), 2.10 (s, 6H); 13C NMR (100 MHz,
CDCl3) d 152.57, 140.74, 140.50, 128.83, 127.88, 127.56, 127.27,
126.91, 125.99, 114.86, 40.52, 22.88, 22.37; 11B NMR (96 MHz,
CDCl3) d 45.18; MS (EI) m/z 343 (M
+, 100). HRMS (EI) calcd for
C23H26BNO 343.21074, found 343.210505.
(N-2,2,2-Trifluoro-ethyl-p-hydroxylanilino)bis(2,6-
dimethylphenyl)borane, 16c
Compound 16c was purified by preparative alumina thin-layer chro-
matography (30% EtOAc/hexanes) to give a light-yellow solid (55%
yield) (mp 113C–115C); 1H NMR (500 MHz, CDCl3) d 7 .14 (t, J =
8.0 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 7.5 Hz, 2H), 6.94 (t,
J = 7.5 Hz, 2H), 6.73 (d, J = 8.0 Hz, 2H), 6.56 (d, J = 8.0 Hz, 2H), 4.62
(s, 1H), 4.07 (q, J = 9.5 Hz, 2H), 2.31 (s, 6H), 2.17 (s, 6H); 13C NMR
(125 MHz, CDCl3) d 153.32, 141.90, 140.41, 140.33, 128.54, 128.08,
127.73, 127.26 (q, J = 281.7 Hz), 127.25, 127.03, 115.19, 54.94 (q,
J = 32.2 Hz), 22.80, 22.13; 19F NMR (470 MHz, CDCl3) d 67.89; 11B
NMR (96 MHz, CDCl3) d 48.56; HRMS (ESI) calcd for C24H25BF3NONH4
429.23250 (M + NH4
+), found 429.2303.
Synthesis of Carbon-Nitrogen Analog of the Anilino Bis(2,6-
dimethylphenyl)boranes, 21
A mixture of N-methyl-p-hydroxyaniline 7c (0.5 mmol) and the benz-
hydryl chloride, 18 (0.5 mmol), in 10 ml acetonitrile was heated at reflux
for 3 days and concentrated in vacuo; the residue was dissolved in ethyl
acetate. The mixture was washed with 0.25 M aqueous NaOH, dried
over sodium sulfate, and concentrated in vacuo. The crude product,
20, was purified by preparative silica gel thin-layer chromatography59–669, June 2007 ª2007 Elsevier Ltd All rights reserved 667
Chemistry & Biology
Elemental Isomerism, B-N as a Surrogate for C=C(20% EtOAc/hexanes). Demethylation of 20 (0.1 mmol) was conducted
by using 30 equivalents of BF3$SMe2 in 5 ml dichloromethane at room
temperature for 48 hr. The reaction mixture was quenched by 2 ml
methanol and 5 ml water and extracted three times with 10 ml ethyl
acetate; the organic layer was washed by brine and dried over K2CO3;
and the pure product was obtained by preparative silica gel thin-layer
chromatography (30% EtOAc/hexanes).
(Bis-[2,6-dimethyl-phenyl]-methylene)-(4-methoxy-phenyl)-
amine, 20
Light yellow viscous oil (25% yield); 1H NMR (500 MHz, CDCl3) d 7.12–
7.15 (m, 2H), 7.08–7.11 (m, 1H), 6.88–6.90 (m, 1H), 6.88 (d, J = 8.0 Hz,
2H), 6.71–6.75 (m, 2H), 6.69 (d, J = 8.0 Hz, 2H), 3.74 (s, 3H), 2.61 (s, 3H),
1.96 (s, 6H), 1.82 (s, 3H); 13C NMR (125 MHz, CDCl3) d 168.22, 156.82,
142.90, 139.94, 139.32, 137.77, 137.16, 136.69, 129.79, 129.57,
128.95, 128.73, 128.43, 123.27, 113.82, 55.54, 22.51, 21.22, 20.65;
HRMS (ESI) calcd for C24H24ONH 344.20143 (M + H
+), found 344.2014.
(Bis-[2,6-dimethyl-phenyl]-methylene)-(4-hydroxy-phenyl)-
amine, 21
Light-yellow solid (55% yield) (mp 58C–60C); 1H NMR (500 MHz,
CDCl3) d 7.14–7.16 (m, 2H), 7.08–7.11 (m, 1H), 6.89–6.91 (m, 1H),
6.88 (d, J = 8.0 Hz, 2H), 6.67–6.69 (m, 2H), 6.62 (d, J = 8.0 Hz, 2H),
4.83 (s, br, 1H), 2.61 (s, 3H), 1.96 (s, 6H), 1.81 (s, 3H); 13C NMR (125
MHz, CDCl3) d 165.50, 153.52, 141.59, 139.84, 136.86, 135.00,
133.62, 129.87, 129.68, 128.64, 128.43, 127.29, 123.76, 120.92,
115.62, 22.50, 21.20, 20.66; HRMS (ESI) calcd for C23H23ONH
330.18578 (M + H+), found 330.1858.
Estrogen Receptor-Binding Affinity
Relative binding affinities were determined by a competitive radiomet-
ric binding assay as previously described [30, 32], by using 10 nM
[3H]estradiol as tracer ([6,7-3H]estra-1,3,5,[10]-triene-3,17b-diol, 51–
53 Ci/mmol, Amersham BioSciences, Piscataway, NJ); purified full-
length human ERa and ERb were purchased from PanVera/Invtrogen
(Carlsbad, CA). Incubations were conducted for 18–24 hr at 0C. Hy-
droxyapatite (BioRad, Hercules, CA) was used to absorb the recep-
tor-ligand complexes, and free ligand was washed away. The binding
affinities are expressed as relative binding affinity (RBA) values; the
RBA of estradiol was set to 100%. The values given are the average ±
range or SD of 2–3 independent determinations. Estradiol binds to ERa
with a KD of 0.2 nM and to ERb with a KD of 0.5 nM.
Gene Transcriptional Activity
Assays were performed as previously described [35, 40]. Human en-
dometrial cancer (HEC-1) cells were maintained in minimum essential
medium (MEM) plus phenol red supplemented with 5% calf serum and
5% fetal calf serum. Cells were plated in phenol red-free Improved
MEM and 5% charcoal dextran-treated calf serum (CDCS) and were
given fresh medium 24 hr before transfection. Transfection assays
were performed in 24-well plates with a mixture of 0.35 ml serum-
free Improved MEM medium and 0.15 ml Hank’s balanced salt solution
containing 5 ml lipofectin (Life Technologies, Inc., Gaithersburg, MD),
1.6 mg transferrin (Sigma, St. Louis, MO), 200 ng pCMV b-galactosi-
dase as internal control, 1 mg 2ERE-pS2-Luc, and 100 ng ER expres-
sion vector per well. The cells were incubated at 37C in a 5% CO2-
containing incubator for 5 hr. The medium was then replaced with fresh
Improved MEM supplemented with 5% CDCS plus the desired con-
centrations of ligands. Cells were harvested 24 hr later. Luciferase
and b-galactosidase activity was assayed as described [40].
Protein Purification and X-Ray Crystallography
The ERa-LBD (298–554) Y537S [29] was expressed in BL21 cells as
a fusion protein with a 6xHis tag and a TEV protease site. After chroma-
tography over a nickel-NTA column and tag cleavage, the protein was
dialyzed into 20 mM Tris-HCl (pH 8), 50 mM NaCl, 10% glycerol, and
50 mM b-mercaptoethanol. The protein was then diluted twice in water
and purified with Q-ion exchange chromatography, eluting at175 mM
NaCl. The protein was concentrated to 10 mg/ml and incubated
overnight with 1 mM compound 9e and 1–2 mM GRIP peptide [28].668 Chemistry & Biology 14, 659–669, June 2007 ª2007 ElseviThe protein-ligand slurry was centrifuged at 15,000 3 g for 15 min,
and the supernatant was used for crystallization trials. The protein
crystallized in 25%–28% (w/v) PEG monomethyl ether 2000, 0.1 M
Bis Tris (pH 6.5). Data were collected at the Structural Biology Center
at the Advanced Photon Source. The data were processed with
HKL2000, and the structure was solved by using molecular replace-
ment with the CCP4 software package. The structure was refined
and rebuilt with CCP4, CNS, XtalView, and Coot software.
Supplemental Data
Supplemental Data include experimental methods for the preparation
and characterization of compounds 6, 7c–7g, 8a, 8b, 8f, 8g, 9f, 9g, 10,
11a, 11b, 15, and 16a and a figure showing the electron density of the
ligand and ERa-LBD-binding pocket residues and are available at
http://www.chembiol.com/cgi/content/full/14/6/659/DC1/.
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